Pitt startup Astria Biosciences continues to rack up milestones as it works to bring the first simple, whole blood-based test to detect the presence and monitor the progression of cerebral aneurysms to market. It’s latest accomplishment: receiving a $275,000 SBIR Phase 1 commercialization grant from the National Science Foundation (NSF). The grant will be applied toward developing a robust data set with a focus on minorities to provide higher test fidelity in high-risk and under-represented patient groups and developing a dynamic rupture risk score that can be used to define novel aneurysm sub-groupings.
From undergrads to PhD candidates, Students Impress Judges with Grasp of Technology and Business Acumen
Company Receives Clearance for Phase I Safety Trial for Treatment of Macular Degeneration. Alan Wells and Cecelia Yates have collaborated on and off for nearly two decades at the University of Pittsburgh developing a class of synthetic proteins that act as switches to turn off the wound healing process. Now, after nearly 7 years of pre-clinical work, the company co-founded and launched from their research has entered a Phase 1 clinical trial with its therapy for the treatment of age-related macular degeneration, also known as wet-AMD.
Three Pitt innovation teams each received $100,000 awards to continue on the path from the lab to market at the 10th annual Pitt Innovation Challenge (PInCh) sponsored by the Clinical and Translational Science Institute (CTSI).